Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis.

Ann Hematol · 2025 · PMC12031939 · PMID 40091126

Europe PMC DOI

hedged sentences

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

a strong trendP = 0.067so close (0.05 < p ≤ 0.1)

33.85%, P = 0.116), the haplo-PBSCT group had a strong trend towards a lower CI of moderate to severe cGVHD at 2 years compared to the MUD/MSD-PBSCT group, with CIs of 8.19% and 23.40%, respectively ( P = 0.067, Fig. 1 c).

also in 5,725 other papers

a decreasing trendno p-value reported

Specifically, compared to the MUD/MSD-PBSCT group, the haplo-PBSCT group showed a decreasing trend of moderate to severe cGVHD (MUD/MSD-PBSCT: 23.40%, haplo-PBSCT: 8.19%), suggesting that dual T-cell depletion with ATG and PTCy is also feasible in elderly haploidentical transplant patients.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.